In just three years, Ozempic and other GLP-1 drugs have revolutionized weight loss—sparking a cultural obsession with thinness, disrupting industries from fast food to fashion, and even threatening to dismantle the body positivity movement. As reported by The Guardian, these drugs, initially designed for type 2 diabetes, are now used by 1 in 8 Americans, often obtained through telehealth services with minimal oversight.
But behind the hype lies a darker question: What happens when a drug designed to suppress appetite falls into the hands of those already fighting disordered eating?
“Drug-Induced Anorexia”: The Danger of Ozempic
Ozempic (semaglutide) and similar medications mimic a hormone that slows digestion, curbing hunger and helping users eat less. For those struggling with anorexia or bulimia, however, this effect can be catastrophic.
“These drugs are rocket fuel for people with eating disorders,” says Dr. Kimberly Dennis, a leading psychiatrist specializing in eating disorders, in an interview with The Guardian.
Some clinicians report cases of “drug-induced anorexia”—patients using Ozempic to dangerously restrict calories, exacerbating malnutrition.
Pamela Keel, a psychologist at Florida State University, warns that GLP-1s not only make restriction easier but may also facilitate purging.
“The stomach empties more slowly on these drugs, which can make vomiting more effective,” she explains.
The Telehealth Loophole
Despite these risks, obtaining Ozempic has never been easier. Telehealth platforms like Hers, Ro, and Eden offer prescriptions after brief online consultations—no in-person doctor required. In one case, a journalist lied about their weight on an intake form and was quickly approved for compounded semaglutide—without ever speaking to a physician.
See also: TikTok’s Dark Side: How Migrant Smugglers Use the App to Lure Desperate Families
A Double-Edged Sword: Can Ozempic Help Binge Eating Disorder?
While GLP-1s pose risks for restrictive eating disorders, emerging research suggests they could help those with binge eating disorder (BED)—a condition affecting millions more than anorexia or bulimia, according to a Harvard report.
Megan, 39, a nurse from New Jersey, struggled with bingeing and purging for decades before trying Ozempic.
“The constant ‘food noise’ in my head just… stopped,” she says. “I finally realized this wasn’t about willpower—it was biological.”
Preliminary studies support these anecdotes, showing GLP-1s may reduce compulsive overeating by regulating hunger hormones.
“For someone with BED, these could be life-changing,” says Leslie Heinberg, a Cleveland Clinic psychologist.
See also: ‘Not Neutrality, But Suppression’: Utah Becomes First State to Ban LGBTQ+ Pride Flags
The Skinny Dilemma: If Thin Becomes Easy, Will We All Want It?
Beyond medical risks, Ozempic forces a societal reckoning: If being thin is just an injection away, will it become the new standard?
Sabrina Strings, a sociologist studying body image, traces today’s thin ideal back to racist Enlightenment-era beliefs equating fatness with lack of control.
“GLP-1s medicalize that old prejudice,” she says.
Morgan, 27, a Chicago marketer who embraced body positivity, still chose Wegovy.
“It felt like a betrayal,” she admits in The Guardian’s reporting. “But the relief was undeniable.”
See also: Pierce Brosnan Sides with Helen Mirren After She Slams James Bond
The Unanswered Question: Will Ozempic Create More Eating Disorders?
With no long-term data, experts fear GLP-1s could “flip a switch” in vulnerable brains, triggering lifelong disorders. Terry Schwartz, an eating disorder specialist at UC San Diego, compares it to Topamax, an anti-seizure drug linked to sudden-onset anorexia.
For now, doctors must carefully screen patients—but as demand surges, oversight lags. Lily, an Australian diabetic with a history of anorexia, relapsed immediately on Ozempic.
“They should have been more careful,” she told The Guardian. “This has been one of the most confusing things I’ve ever done to my body.”
Ozempic isn’t just a medical breakthrough—it’s a mirror. In our rush to “fix” our bodies, we must ask: Why are we so eager to trade starvation, obsession, and lifelong dependency for society’s approval? These drugs expose the brutal calculus of fatphobia: that being thin is worth any cost, even if it means outsourcing our eating disorders to Big Pharma. The real question isn’t whether Ozempic works, but why we’ve decided thinness is a virtue worth suffering for—and who profits when we keep believing it.
